

Highly Specialised Technologies Evaluation Committee Interests Register

Topic: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no minimal residual disease [ID6405]

Publication Date: 26 March 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Emtiyaz Chowdhury	HST Committee Member	Non-Financial Professional interests	Emtiyaz is employed by Parexel. Parexel is a CRO that works with the manufacturer. Emtiyaz has not been directly involved in providing any services related to this specific technology or indication.	06/01/2025	It was agreed that Emtiyaz's declaration would not prevent them from participating in discussions on this appraisal.
Calum Goodfellow	Patient Expert	Non-Financial Professional interests	Calum declared the following interests: My employer Leukaemia Care has received funding from Amgen, Jazz Pharmaceuticals and Pfizer.	16/01/2025	It was agreed that Calum's declaration would not prevent them from providing expert advice to the committee.